Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,592
  • Shares Outstanding, K 1,633
  • Annual Sales, $ 0 K
  • Annual Income, $ -120 K
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.09
Trade REVB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -5.39
  • Number of Estimates 2
  • High Estimate -1.77
  • Low Estimate -9.00
  • Prior Year -15.32
  • Growth Rate Est. (year over year) +64.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.78 +15.44%
on 04/15/24
2.52 -18.45%
on 04/11/24
-0.25 (-11.04%)
since 04/10/24
3-Month
1.78 +15.44%
on 04/15/24
4.34 -52.65%
on 02/28/24
-0.72 (-26.08%)
since 02/09/24
52-Week
1.78 +15.44%
on 04/15/24
39.00 -94.73%
on 05/22/23
-33.04 (-94.15%)
since 05/10/23

Most Recent Stories

More News
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today statistically significant results in a validated preclinical model of acute and chronic kidney disease....

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol “REVBU” will...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...

REVB : 2.06 (-6.36%)
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...

REVB : 2.06 (-6.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revelation Biosciences Inc. is a clinical-stage life sciences company. It focused on the development of immunologic-based therapies for the prevention and treatment of disease. The company's product pipeline includes REVTx-99, REVTx-200 and REVDx-501. Revelation Biosciences Inc., formerly known as Petra...

See More

Key Turning Points

3rd Resistance Point 2.42
2nd Resistance Point 2.38
1st Resistance Point 2.29
Last Price 2.06
1st Support Level 2.15
2nd Support Level 2.10
3rd Support Level 2.01

See More

52-Week High 39.00
Fibonacci 61.8% 24.78
Fibonacci 50% 20.39
Fibonacci 38.2% 16.00
Last Price 2.06
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar